All News

Recognize Cushing syndrome in primary care: key clinical clusters, first-line screening tests (DST, salivary cortisol, UFC), and when to refer to endocrinology.

Sublingual epinephrine film matches adult PK/PD in kids aged 7-17 with a history of allergic reactions and high risk for serious allergic reactions, incluing anaphylaxis.

Regulatory update aims to align labeling with current evidence on menopausal hormone therapy safety and benefits

Merck's oral PCSK9 inhibitor enlicitide demonstrated antibody-like LDL-C lowering in adutls with HeFH with safety profile similar to placebo in phase 3 trial.

Phase 2b findings show rezpegaldesleukin reduced ACQ-5 scores and improved key AD endpoints in participants with comorbid asthma.

The findings showed evolocumab reduced risk of first major MACE by 25% and risk of first MI by 36%. Full study findings are published in NEJM.

Submission of the sNDA suggests a potential FDA decision on the dextromethorphan-bupropion combination sometime during the first quarter of 2026.

Explore key clinical takeaways from FMX 2025, including updates on CGM, chronic cough, AAA screening, immunization, and more.

This new episode covers global diabetes gaps, salt substitute use, influenza vaccine safety, vaginal estradiol, and preconception CT risks.

Your daily dose of the clinical news you may have missed.

Nearly 40% of REDEFINE 1 participants taking antihypertensive medications reduced or discontinued their blood pressure drugs during the trial, Novo Nordisk reported.

Adults with diabetes often face obstacles to optimal disease management in the workplace. Use this checklist in the clinic to help them navigate the barriers.

New research suggests hormone therapy may increase autoimmune disease risk in postmenopausal women. Dr Jiang discusses early findings and clinical implications.

TMS 2025: Dr Marla Shapiro doesn't start perimenopausal therapy without an answer to the most important question: "What is your most bothersome symptom?"

Trump announces deals with Eli Lilly and Novo Nordisk slashing GLP-1 prices to as low as $150/month, expanding Medicare coverage starting mid-2026.

Oral semaglutide 25 mg improved glucose control and CV risk factors across weight loss categories in OASIS 4 post hoc analysis presented at ObesityWeek 2025.

As adjunctive treatment, lumateperone is associated with early symptom improvement, good tolerability, and provides a practical no-titration option for adults with persistent MDD.

Novo Nordisk’s STEP UP trial shows semaglutide delivers 21% weight loss and reduces key cardiovascular and metabolic risk factors in obesity management.